


## AT-9283 L-lactate

## Chemical Properties

CAS No. :	896466-76-5
Formula:	C <sub>22</sub> H <sub>29</sub> N <sub>7</sub> O <sub>5</sub>
Molecular Weight:	471.52
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	AT-9283 L-lactate is an inhibitor of aurora kinase.
Targets(IC50)	Apoptosis,Others,FLT,Bcr-Abl,Aurora Kinase,Autophagy,JAK

## Solubility Information

Solubility	DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1208 mL	10.604 mL	21.208 mL
5 mM	0.4242 mL	2.1208 mL	4.2416 mL
10 mM	0.2121 mL	1.0604 mL	2.1208 mL
50 mM	0.0424 mL	0.2121 mL	0.4242 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Duong JK, Griffin MJ, Hargrave D, Vormoor J, Edwards D, Boddy AV. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia. *Br J Clin Pharmacol*. 2017 Aug;83(8):1713-1722. doi: 10.1111/bcp.13260. Epub 2017 Mar 5. PubMed PMID: 28177130; PubMed Central PMCID: PMC5510070.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. *Pediatr Blood Cancer*. 2017 Jun;64(6). doi: 10.1002/pbc.26351. Epub 2016 Dec 1. PubMed PMID: 27905678.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. *Leuk Lymphoma*. 2016;57(6):1463-6. doi: 10.3109/10428194.2015.1091927. Epub 2015 Oct 15. PubMed PMID: 26376958.

Moawad EY. Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel. *J Gastrointest Cancer*. 2015 Dec;46(4):380-9. doi: 10.1007/s12029-015-9761-9. PubMed PMID: 26346504.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481